Page 121 - 《中国药房》2024年3期

tients with HER2 metastatic breast cancer after lapatinib catinib versus placebo added to trastuzumab and
+
and trastuzumab treatment （KCSG BR11-16）[J]. Br J capecitabine for patients with pretreated HER2 metastatic
+
Cancer，2019，121（12）：985-990. breast cancer with and without brain metastases
[17] UNTCH M，MINCKWITZ G V，GERBER B，et al. Sur‐ （HER2CLIMB）：final overall survival analysis[J]. Ann
vival analysis after neoadjuvant chemotherapy with trastu‐ Oncol，2022，33（3）：321-329.
zumab or lapatinib in patients with human epidermal [24] HARBECK N，HUANGC S，HURVITZ S，et al. Afatinib
growth factor receptor 2-positive breast cancer in the ge‐ plus vinorelbine versus trastuzumab plus vinorelbine in pa‐
parquinto （G5） Study （GBG 44）[J]. J Clin Oncol，2018， tients with HER2-overexpressing metastatic breast cancer
36（13）：1308-1316. who had progressed on one previous trastuzumab treat‐
[18] FERNANDEZ-MARTINEZ A，KROP I E，HILLMAN D ment （LUX-Breast 1）：an open-label，randomised，phase 3
W，et al. Survival，pathologic response，and genomics in trial[J]. Lancet Oncol，2016，17（3）：357-366.
CALGB 40601 （alliance），a neoadjuvant phase Ⅲ trial of [25] WU J，JIANG Z F，LIU Z Z，et al. Neoadjuvant pyrotinib，
paclitaxel-trastuzumab with or without lapatinib in HER2- trastuzumab，and docetaxel for HER2-positive breast can‐
positive breast cancer[J]. J Clin Oncol，2020，38（35）： cer （PHEDRA）：a double-blind，randomized phase 3 trial
4184-4193. [J]. BMC Med，2022，20（1）：498.
[19] TAKANO T，TSURUTANI J，TAKAHASHI M，et al. A [26] XU B，YAN M，MA F，et al. LBA19 Pyrotinib or placebo
randomized phase Ⅱ trial of trastuzumab plus in combination with trastuzumab and docetaxel for HER2-
capecitabine versus lapatinib plus capecitabine in patients positive metastatic breast cancer （PHILA）：a randomized
with HER2-positive metastatic breast cancer previously phase Ⅲ trial[J]. Ann Oncol，2022，33：S1387.
treated with trastuzumab and taxanes：WJOG6110B/ [27] DING Y Q，MO W J，XIE X H，et al. Pyrotinib as neoadju‐
ELTOP[J]. Breast，2018，40：67-75. vant therapy for HER2+ breast cancer：a multicenter，ran‐
[20] PICCART-GEBHART M，HOLMES E，BASELGA J，et domized，controlled，phase Ⅱ trial[J]. J Clin Oncol，2021，
al. Adjuvant lapatinib and trastuzumab for early human 39（15_suppl）：574.
epidermal growth factor receptor 2-positive breast cancer： [28] JIANG Z F，YAN M，BIAN L，et al. Abstract PD8-05：
results from the randomized phase Ⅲ adjuvant lapatinib overall survival （OS） results from the phase Ⅲ PHENIX
and/or trastuzumab treatment optimization trial[J]. J Clin trial of HER2+ metastatic breast cancer treated with pyro‐
Oncol，2016，34（10）：1034-1042. tinib plus capecitabine[J]. Cancer Res， 2022， 82
[21] AWADA A，COLOMER R，INOUE K，et al. Neratinib （4_Supplement）：5.
plus paclitaxel vs trastuzumab plus paclitaxel in pre- [29] YAN M，BIAN L，HU X C，et al. Pyrotinib plus
viously untreated metastatic ERBB2-positive breast capecitabine for human epidermal growth factor receptor
cancer：the NEfERT-T randomized clinical trial[J]. JAMA 2-positive metastatic breast cancer after trastuzumab and
Oncol，2016，2（12）：1557-1564. taxanes （PHENIX）：a randomized，double-blind，placebo-
[22] CHAN A，MOY B，MANSI J，et al. Final efficacy results controlled phase 3 study[J]. Transl Breast Cancer Res，
of neratinib in HER2-positive hormone receptor-positive 2020，1：13.
early-stage breast cancer from the phase Ⅲ ExteNET trial （收稿日期：2023-05-09 修回日期：2023-10-24）
[J]. Clin Breast Cancer，2021，21（1）：80-91. （编辑：刘明伟）
[23] CURIGLIANO G，MUELLER V，BORGES V，et al. Tu‐

中国药房 2024年第35卷第3期 China Pharmacy 2024 Vol. 35 No. 3 · 367 ·